Oxford Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Oxford Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-650	Closed	-$210K	–	2122
2019 Q3	$210K	Sell	650 -305	-32%	-$98.5K	0.01%	1564
2019 Q2	$412K	Buy	955 +481	+101%	+$238K	0.01%	1346
2019 Q1	$268K	Buy	+474	New	+$227K	0.01%	1439
2018 Q3	–	Sell	-227	Closed	-$131K	–	1948
2018 Q2	$131K	Sell	227 -1,414	-86%	-$1.1M	﹤0.01%	1626
2018 Q1	$4.44M	Buy	+1,641	New	+$3.99M	0.09%	221

Other funds holding VYNE

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oxford Asset Management's VYNE Position: Q4 2019 in Review

Oxford Asset Management sold out of VYNE Therapeutics (VYNE) in Q4 2019, closing a stake of 650 shares — an estimated $210K sold.

Oxford Asset Management first reported a position in VYNE in Q1 2018 and held it in 5 quarters. The position peaked at $4.44M in Q1 2018. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2019.

Oxford Asset Management reported no remaining VYNE Therapeutics position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 650 VYNE Therapeutics shares in Q4 2019, an estimated $210K.
Oxford Asset Management first reported a position in VYNE Therapeutics in Q1 2018 and held it in 5 quarters.
Oxford Asset Management's VYNE Therapeutics position peaked at $4.44M in Q1 2018.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.